Abstract
Objectives Identifying the contribution of biological sex to the heterogeneity in presentation and progression of Parkinson’s disease (PD).
Background The different prevalence of Parkinson’s disease (PD) in men and women suggests that sex-associated mechanisms influence disease mechanisms. Investigating the contribution of sex to disease heterogeneity may uncover disease processes, and lead to new therapeutic targets. Also, understanding these differences in phenotypes will result in better patient management and the planning of more efficient clinical trials.
Methods We tested 40 clinical phenotypes using longitudinal clinic-based patient cohorts consisting of 5,946 patients with a median follow-up of 3.1 years. For continuous outcomes, we used linear regressions at baseline to test the sex-associated differences in presentation, and linear mixed-effects models to test the sex-associated differences in progression. For binomial outcomes, we used logistic regression models at baseline and Cox models for survival analyses. We adjusted for age, disease duration and dopaminergic medication usage. In the secondary analyses, data from 28,809 PD patients and 10,556 non-PD participants from Fox Insight, an online-only self-assessment cohort for PD research, were analyzed to check whether the sex-associated differences observed in the primary analyses were consistent in the cohort and whether the differences were unique to PD or not.
Results Female PD patients had a higher risk for developing dyskinesia early during the follow-up period; with a slower progression in their difficulties of activities of daily living as measured by the Unified Parkinson’s Disease Rating Scale Part II (classic/MDS-revised version); and a lower risk of developing cognitive impairment than male patients. The findings in the longitudinal clinic-based cohorts were mostly consistent with the results in the online-only cohort.
Conclusions This large-scale analysis observed the sex contribution to the heterogeneity of Parkinson’s disease. The results highlight the necessity of future research of the underlying mechanism and importance of personalized clinical management.
Competing Interest Statement
Hirotaka Iwaki: grants, Michael J. Fox Foundation, Jodi Maple-Grødem: grants, Norwegian Parkinson's Disease Association, Norwegian Health Association. Jean-Christophe Corvol: advisory boards, Biogen, Air Liquide, BrainEver, Theranexus, BMS, Zambon, Pfizer, Ipsen, Abbvie; grants, Michael J. Fox Foundation, Actelion, Ipsen. Lasse Pihlstrøm: grants, Norwegian Health Association, South-East Norway Regional Health Authority, Norwegian Parkinson Research Fund, Michael J. Fox Foundation. Khanh-Dung H. Nguyen: stock ownership in medically related fields, Biotech/Pharmaceutical Industry. Kirsten M. Scott: grants, Wellcome Trust PhD Fellowship. Vivianna M. Van Deerlin: grants, National Institutes of Health NS-053488. Aaron G. Day-Williams: stock ownership in medically related fields, Biogen, Merck. Alexis Brice: advisory boards, FWO, ERC; grants, JPND, ANR, Eranet Neuron, Association France Parkinson. Alastair J. Noyce: honoraria, Britannia Pharmaceuticals; grants, Parkinson's UK (G-1606). Jonathan R. Evans: advisory boards, AbbVie, Global Kinetics, Allergan; honoraria, UCB, Allergan, AbbVie. David P. Breen: grants, Wellcome Clinical Research Career Development Fellowship. Karol Estrada: stock ownership in medically related fields, Biogen. David K. Simon: consultancies, Lysosomal Therapeutics, Inc.; advisory boards, Weston Brain Institute; honoraria, Parkinson Study Group, Harvard Medical School, Michael J. Fox Foundation, Biogen; grants, National Institutes of Health, Weston Brain Institute, Mission Therapeutics, Inc., and BioElectron Technologies. Bernard Ravina: stock ownership in medically related fields, Voyager Therapeutics; consultancies, Michael J. Fox Foundation. Mathias Toft: grants, Research Council of Norway, South-Eastern Norway Regional Health Authority, Michael J. Fox Foundation, Norwegian Parkinson Research Fund. Bastiaan R. Bloem: consultancies, Abbvie, Zambon; advisory boards, Michael J. Fox Foundation; honoraria, speaker fees from Abbvie, Zambon, Bial; grants, Netherlands Organization for Scientific Research, the Michael J. Fox Foundation, UCB, Abbvie, the Stichting Parkinson Fonds, the Hersenstichting Nederland, the Parkinson's Foundation, Verily Life Sciences, the Topsector Life Sciences and Health, and the Parkinson Vereniging. Daniel Weintraub: consultancies, Acadia, Alkahest, Anavex Life Sciences, BlackThorn Therapeutics, Bracket, Clintrex LLC, Sunovion, Theravance Biopharma, and the CHDI Foundation. Roger A. Barker: consultancies, FCDI, LCT, BlueRock, Nova Nordisk, Cellino, Locate-Bio; royalties, Springer; Wiley; grants, EU, NIHR, PUK, CPT, Rosetrees Trust, MRC, Wellcome Trust, Evelyn Trust. Caroline H. Williams-Gray: consultancies, Evidera/GSK; speaker honoraria, Profile Pharma Ltd; funding, RCUK/UKRI Research Innovation Fellowship awarded by the Medical Research Council, Cambridge Centre for Parkinson-Plus, NIHR Cambridge Biomedical Research Centre, Michael J. Fox Foundation, the Rosetrees Trust, the Evelyn Trust, Parkinson's UK, Cure Parkinson's Trust. Bart P. van de Warrenburg: advisory boards, member of medical advisory boards patient organizations; royalties, Bohn Stafleu van Loghum (for chapter in Dutch Neurology textbook); grants, Radboud University Medical Centre, ZonMW, Hersenstichting, uniQure, and Gossweiler Foundation. Jacobus J. Van Hilten: grants, The Alkemade-Keuls Foundation, Stichting Parkinson Fonds, Parkinson Vereniging, The Netherlands Organisation for Health Research and Development. Clemens R. Scherzer: grants, National Institutes of Health Grants U01NS082157, U01NS095736, U01NS100603; consultancies, Sanofi. Mike A. Nalls: consultancies, Lysosomal Therapies Inc., Vivid Genomics Inc., Kleiner Perkins Caufield & Byers, Neuron23, Inc., Michael J. Fox Foundation. Ole A. Andreassen Consultant HealthLytix
Funding Statement
The Intramural Research Program the National Institute on Aging (NIA, Z01-AG000949-02), Biogen Idec, and the Michael J Fox Foundation for Parkinson's Research
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding support: The Intramural Research Program the National Institute on Aging (NIA, Z01-AG000949-02), Biogen Idec, and the Michael J Fox Foundation for Parkinson’s Research
Data Availability
Qualified investigators can request raw data through the organizations' homepages (PDBP: https://pdbp.ninds.nih.gov/, PPMI: https://www.ppmi-info.org/, Fox Insight:https://foxinsight.michaeljfox.org/) or collaboration.
